Illumina公司近日宣布，其Trusight™ Oncology Comprehensive产品已获得美国医疗保险和医疗补助服务中心（CMS）的报销批准。这一重要进展将显著提升精准肿瘤学检测的可及性，使更多患者能够受益于先进的基因测序技术。
该报销资格的获批，意味着符合条件的美國患者在进行相关肿瘤基因检测时，可通过医疗保险获得费用覆盖。此举不仅降低了患者的经济负担，也为精准肿瘤治疗的推广提供了有力支持。
Trusight™ Oncology Comprehensive作为一款全面的肿瘤基因检测产品，能够帮助医生更准确地制定个性化治疗方案。随着CMS报销政策的落实，预计将有更多医疗机构采用这项技术，从而推动精准医疗在肿瘤领域的广泛应用。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.